Quick Answer
Silo Pharma, Inc. reported Total Revenue of $72.1 thousand for fiscal year 2025.
Silo Pharma, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $72.1K +0.0% |
$72.1K +0.0% |
$72.1K +0.0% |
$72.1K | — | $40.9K +0.9% |
| Net Income | -$4.23M +3.8% |
-$4.39M -18.7% |
-$3.70M +5.3% |
-$3.91M -200.1% |
$3.90M +228.5% |
-$3.04M -199.8% |
| Diluted EPS | -$0.50 +58.0% |
-$1.19 +0.8% |
-$1.20 | — | $0.04 +180.0% |
-$0.05 |
| Total Assets | $7.61M +2.6% |
$7.41M -4.3% |
$7.75M -33.5% |
$11.64M +11.0% |
$10.49M +635.3% |
$1.43M +188.9% |
| Cash and Equivalents | $4.75M +21.6% |
$3.91M +10.8% |
$3.52M -69.0% |
$11.37M +15.6% |
$9.84M +771.8% |
$1.13M +909.7% |
| Stockholders Equity | $6.31M +25.3% |
$5.03M -18.5% |
$6.18M -40.3% |
$10.34M +14.1% |
$9.06M +607.6% |
$1.28M +5694.5% |
| R&D Expense | $2.16M -8.8% |
$2.37M +180.2% |
$845.1K -34.3% |
$1.29M +85.4% |
$693.9K +2543.5% |
$26.2K |
| Operating Income | -$4.28M +9.0% |
-$4.71M -22.0% |
-$3.86M -6.3% |
-$3.63M -32.2% |
-$2.74M -24.6% |
-$2.20M -136.6% |
| Gross Profit | $27.8K -58.0% |
$66.3K +0.0% |
$66.3K +0.0% |
$66.3K +0.0% |
$66.3K +149.0% |
-$135.2K -1125.7% |
| Shares Outstanding | 13.32M +197.0% |
4.48M +54.3% |
2.91M -8.0% |
3.16M +60.1% |
1.97M -97.7% |
85.14M +260.7% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $18.0K | +0.0% | +0.0% |
| Net Income | September 30, 2025 | -$1.11M | -19.6% | +7.8% |
| Diluted EPS | September 30, 2025 | -$0.12 | +45.5% | +36.8% |
| Total Assets | September 30, 2025 | $6.38M | -25.5% | -4.0% |
| Cash and Equivalents | September 30, 2025 | $3.92M | -19.4% | -9.6% |
| Stockholders Equity | September 30, 2025 | $5.01M | -26.1% | +1.9% |
| R&D Expense | September 30, 2025 | $543.6K | +5.0% | -24.2% |
| Operating Income | September 30, 2025 | -$1.15M | -14.0% | +7.8% |
| Gross Profit | September 30, 2025 | -$2.7K | -116.1% | -116.1% |
| Shares Outstanding | September 30, 2025 | 10.46M | +133.3% | +20.9% |
- Silo Pharma, Inc. reported Total Revenue of $72.1 thousand for fiscal year 2025.
- Silo Pharma, Inc. showed an increase of +0.0% in Total Revenue compared to the prior fiscal year.
- Silo Pharma, Inc. reported Net Income of -$4.23 million for fiscal year 2025.
- Silo Pharma, Inc. showed an increase of +3.8% in Net Income compared to the prior fiscal year.
- Silo Pharma, Inc. reported Diluted EPS of $0.50 per share (loss) for fiscal year 2025.
- Silo Pharma, Inc. showed an increase of +58.0% in Diluted EPS compared to the prior fiscal year.
- Silo Pharma, Inc. reported Total Assets of $7.61 million for fiscal year 2025.
- Silo Pharma, Inc. showed an increase of +2.6% in Total Assets compared to the prior fiscal year.
- Silo Pharma, Inc. reported Cash and Equivalents of $4.75 million for fiscal year 2025.
- Silo Pharma, Inc. showed an increase of +21.6% in Cash and Equivalents compared to the prior fiscal year.
- Silo Pharma, Inc. reported Stockholders Equity of $6.31 million for fiscal year 2025.
- Silo Pharma, Inc. showed an increase of +25.3% in Stockholders Equity compared to the prior fiscal year.
- Silo Pharma, Inc. reported R&D Expense of $2.16 million for fiscal year 2025.
- Silo Pharma, Inc. showed a decrease of -8.8% in R&D Expense compared to the prior fiscal year.
- Silo Pharma, Inc. reported Operating Income of -$4.28 million for fiscal year 2025.
- Silo Pharma, Inc. showed an increase of +9.0% in Operating Income compared to the prior fiscal year.
- Silo Pharma, Inc. reported Gross Profit of $27.8 thousand for fiscal year 2025.
- Silo Pharma, Inc. showed a decrease of -58.0% in Gross Profit compared to the prior fiscal year.
- Silo Pharma, Inc. reported Shares Outstanding of 13.32 million shares for fiscal year 2025.
- Silo Pharma, Inc. showed an increase of +197.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: